These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 27053113)
1. The Stability and Expression Level of Bok Are Governed by Binding to Inositol 1,4,5-Trisphosphate Receptors. Schulman JJ; Wright FA; Han X; Zluhan EJ; Szczesniak LM; Wojcikiewicz RJ J Biol Chem; 2016 May; 291(22):11820-8. PubMed ID: 27053113 [TBL] [Abstract][Full Text] [Related]
2. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage. Schulman JJ; Wright FA; Kaufmann T; Wojcikiewicz RJH J Biol Chem; 2013 Aug; 288(35):25340-25349. PubMed ID: 23884412 [TBL] [Abstract][Full Text] [Related]
3. Bok regulates mitochondrial fusion and morphology. Schulman JJ; Szczesniak LM; Bunker EN; Nelson HA; Roe MW; Wagner LE; Yule DI; Wojcikiewicz RJH Cell Death Differ; 2019 Dec; 26(12):2682-2694. PubMed ID: 30976095 [TBL] [Abstract][Full Text] [Related]
4. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation. Vervliet T; Parys JB; Bultynck G Biochem Soc Trans; 2015 Jun; 43(3):396-404. PubMed ID: 26009182 [TBL] [Abstract][Full Text] [Related]
5. Endogenous Bok is stable at the endoplasmic reticulum membrane and does not mediate proteasome inhibitor-induced apoptosis. Bonzerato CG; Keller KR; Schulman JJ; Gao X; Szczesniak LM; Wojcikiewicz RJH Front Cell Dev Biol; 2022; 10():1094302. PubMed ID: 36601536 [TBL] [Abstract][Full Text] [Related]
6. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond. Monaco G; Vervliet T; Akl H; Bultynck G Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373 [TBL] [Abstract][Full Text] [Related]
7. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2 and IP Ivanova H; Wagner LE; Tanimura A; Vandermarliere E; Luyten T; Welkenhuyzen K; Alzayady KJ; Wang L; Hamada K; Mikoshiba K; De Smedt H; Martens L; Yule DI; Parys JB; Bultynck G Cell Mol Life Sci; 2019 Oct; 76(19):3843-3859. PubMed ID: 30989245 [TBL] [Abstract][Full Text] [Related]
9. Bok binds to a largely disordered loop in the coupling domain of type 1 inositol 1,4,5-trisphosphate receptor. Szczesniak LM; Bonzerato CG; Schulman JJ; Bah A; Wojcikiewicz RJH Biochem Biophys Res Commun; 2021 May; 553():180-186. PubMed ID: 33773141 [TBL] [Abstract][Full Text] [Related]
10. BOK controls apoptosis by Ca Carpio MA; Means RE; Brill AL; Sainz A; Ehrlich BE; Katz SG Cell Rep; 2021 Mar; 34(10):108827. PubMed ID: 33691099 [TBL] [Abstract][Full Text] [Related]
11. The role of Ca2+ in triggering inositol 1,4,5-trisphosphate receptor ubiquitination. Alzayady KJ; Wojcikiewicz RJ Biochem J; 2005 Dec; 392(Pt 3):601-6. PubMed ID: 16134970 [TBL] [Abstract][Full Text] [Related]
12. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227 [TBL] [Abstract][Full Text] [Related]
13. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. Ivanova H; Vervliet T; Missiaen L; Parys JB; De Smedt H; Bultynck G Biochim Biophys Acta; 2014 Oct; 1843(10):2164-83. PubMed ID: 24642269 [TBL] [Abstract][Full Text] [Related]
14. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor. Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498 [TBL] [Abstract][Full Text] [Related]
15. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541 [TBL] [Abstract][Full Text] [Related]
17. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function. Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545 [TBL] [Abstract][Full Text] [Related]
18. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071 [TBL] [Abstract][Full Text] [Related]
19. Defining the stoichiometry of inositol 1,4,5-trisphosphate binding required to initiate Ca2+ release. Alzayady KJ; Wang L; Chandrasekhar R; Wagner LE; Van Petegem F; Yule DI Sci Signal; 2016 Apr; 9(422):ra35. PubMed ID: 27048566 [TBL] [Abstract][Full Text] [Related]
20. Bcl-xL acts as an inhibitor of IP Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]